ARX788 in HER2-positive Metastatic Breast Cancer Patients

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Nov 20, 2025 → Nov 20, 2027
See other at-risk trials from Henan Cancer Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Nov 20, 2025 to Nov 20, 2027 Show 5 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Nov 20, 2024 to Jun 16, 2025
    • Study sites: 0 to 1
    • Eligibility criteria expanded, about 23 words
    • Secondary endpoints: details revised at 1 of 15 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.
Trial Details
NCT Number NCT06663748
Lead Sponsor Henan Cancer Hospital
Conditions
(from sponsor)		 HER2-positive, Metastatic Breast Cancer
Related terms Breast Neoplasms
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov